Landfar(SZ:000504)2023-04-20 16:00Financial Performance - The company's operating revenue for 2022 was ¥200,345,457.02, representing a 27.92% increase compared to ¥156,618,305.30 in 2021[21]. - The net profit attributable to shareholders was -¥12,694,776.12, an improvement of 33.63% from -¥19,125,950.55 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,050,428.56, a 21.53% improvement from -¥29,373,370.76 in 2021[21]. - Cash generated from operating activities increased by 55.35% to ¥166,381,243.04, up from ¥107,098,005.73 in 2021[21]. - The total assets at the end of 2022 were ¥553,064,727.36, a decrease of 16.11% from ¥659,245,600.20 at the end of 2021[26]. - The net assets attributable to shareholders decreased by 17.24% to ¥13,771,203.62 from ¥16,640,394.08 in 2021[26]. - The company reported a weighted average return on equity of -123.33% for 2022, compared to -112.47% in 2021[26]. - The company received government subsidies amounting to ¥6,829,849.35 in 2022, down from ¥8,630,913.98 in 2021[28]. - The total non-operating income and expenses for 2022 amounted to ¥10,355,652.44, slightly higher than ¥10,247,420.21 in 2021[29]. Business Strategy and Focus - The company has undergone a strategic adjustment in its major business focus from real estate and publishing to biomedicine and cell technology services since 2015[20]. - The company is actively involved in research and development in new products and technologies within the biomedicine sector[20]. - The company is positioned in a growing stem cell industry, with increasing government support for research and application in this field[33]. - The company aims to enhance the quality, reliability, and traceability of its products and services through information management and standard operating procedures[43]. - The company is focused on integrating existing R&D resources to create a tiered development framework in the biopharmaceutical field[103]. Revenue Breakdown - The company's total revenue for the reporting period was 200.35 million yuan, with the biopharmaceutical segment generating 142.70 million yuan, an increase of 18.15% year-on-year, and the energy-saving and environmental protection segment generating 57.48 million yuan, an increase of 60.35% year-on-year[42]. - The revenue from the energy-saving technology service sector was ¥57,480,136.60, accounting for 28.69% of total revenue, with a significant growth of 60.35% from ¥35,845,757.38 in 2021[58]. - The biopharmaceutical sector generated ¥142,696,749.00, which is 71.23% of total revenue, reflecting an 18.15% increase from ¥120,772,547.92 in the previous year[58]. - The revenue from cell storage and testing services was ¥135,930,334.24, which accounted for 67.85% of the total revenue from the biopharmaceutical sector[58]. Research and Development - The company has submitted nearly 30 intellectual property applications in the past three years, demonstrating its commitment to research and technology innovation in the field of stem cell storage and clinical applications[43]. - R&D investment increased by 16.88% to ¥9,985,226.68 in 2022, accounting for 4.98% of operating revenue[73]. - The company is in the project initiation phase for a new hydrogel scaffold material for mesenchymal stem cell transplantation, aiming to provide experimental data for clinical research[71]. - The company has completed the extraction and quality control process for mesenchymal stem cell exosomes, which may fill a gap in the field of stem cell exosome quality control[72]. Governance and Management - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operations, and no fund occupation by the controlling shareholder[116]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[117]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[120]. - The company has committed to compliance and governance, with independent directors and a dedicated audit team ensuring transparency and accountability[138][140]. Market Expansion and Future Plans - In 2023, the company aims to optimize its asset-liability structure and enhance its financial resilience by issuing shares to specific investors, which is currently in progress[102]. - The company plans to strengthen its R&D capabilities by collaborating with research institutions and universities, focusing on stem cell and immune cell technologies[103]. - Market expansion plans include entering two new provinces, targeting an additional 500,000 users[147]. - The company has completed a strategic acquisition of a local biotech firm for 100 million yuan to enhance its product portfolio[147]. Employee and Talent Management - The total number of employees at the end of the reporting period was 512, with 287 in sales and 58 in production[164]. - The educational background of employees includes 7 with a doctorate, 33 with a master's degree, and 160 with a bachelor's degree[165]. - The company has implemented a training program that includes internal, external, and online training methods[166]. - The company emphasizes the importance of talent development and plans to build a robust talent cultivation system to support its strategic goals[105]. Legal and Compliance - The company faced a lawsuit regarding a technical authorization agreement, with a claimed amount of CNY 737.99 million, but it has not formed a provision for this liability[197]. - The company has not faced any penalties or rectifications during the reporting period[200]. - The company has not engaged in any illegal occupation of assets or funds during the reporting period[189]. Financial Management - The company reported a significant increase in cash flow from its cell storage business, contributing positively to cash flow despite overall net losses[80]. - The company has committed to avoiding any form of competition with its controlling shareholders and related enterprises[186]. - The company guarantees that all related transactions will be conducted at market prices and in compliance with relevant regulations[187].